 Eli Lilly's diabetes drug, Monjaro, gained Chinese regulatory approval for weight loss today. Last month, Novo Nordisk's Ozempic received the same approval, fueling competition in a nation that's among the world's most severely hit by obesity. Erica Herskowitz, Bloomberg Radio. Want Amazon, Spotify, and Netflix all in one place, all for free? Not possible, you say.